Investing in Biotech Stocks

    

“In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my objective insights on markets, sectors, and companies.”

Sam Subramanian PhD, MBA, Editor, AlphaProfit MoneyMatters

Biotech Stocks and ETFs: Should You Board the Biotech Bandwagon Now?

July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer.… Read More »

What’s Driving Biotech

Biotechnology, which has been on a roll, declined after the much-anticipated American Society of Clinical Oncologists meeting in early June in New Orleans, where cancer specialists deliberated on the merits of new treatments. The two extant ETFs which focus on this industry are iShares Nasdaq Biotechnology (AMEX:IBB) and Biotech HOLDRs (AMEX:BBH). Before deciding to dump or load up… Read More »

Playing the High-Stakes Biotech Game

Investing in biotech stocks has never been for the faint-hearted as many biotech companies have high cash burn rates. The biotech industry however has a few things going for it. Read on to learn more about investment opportunities in this industry. Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting in… Read More »

Biotech Funds FBIOX

The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »

New ETF and Mutual Fund Recommendations

The Fidelity and ETF Core and Focus model portfolios have gained at annualized rates of 14.5% and 17.7%, respectively since 1994. The model portfolios will be repositioned with new mutual fund and ETF recommendations on Monday, September 30. Learn more about AlphaProfit's Free and Premium Service investment newsletters.

Free Investment Newsletter MoneyMatters

  • Independent analysis of the economy, markets, and sectors
  • Unbiased ETF, stock, and mutual fund advice and evaluations
  • Unique insights on emerging profit opportunities and must-know threats
  • Complimentary access to premium service
  • Subscription discounts for premium service
special_report

  • Five Smart Ways of Using Sector Funds and ETFs with inside scoop on sector investments
  • Three Key Mistakes to Avoid when Investing in Sector ETFs
LEAVE THIS BLANK

No Spam We respect your privacy. We do not spam or sell your personal information to anyone else, period.

Premium Service Investment Newsletter

Clear, Actionable Advice on Sectors, Funds, ETFs, & Stocks

  • Specific guidance on what and when to buy or sell
  • Long-term investing and short-term trading recommendations
  • Proven strategies for all markets
  • 75% win-rate including 2008 crash and dot-com bust

Market-beating model portfolios

  • Suitable for small and large accounts sizes
  • Appropriate for different investment objectives and account types
  • Results verifiable in login area with free account
  • Track record of smashing market 7-to-1

Priceless intangibles

  • All recommendations provided ahead of time with ample notice
  • Unbiased, independent advice with no axes to grind
  • 24/7 access to premium service and its archives
  • Access to Dr. Sam Subramanian via e-mail

THE GOOD NEWS JUST BEGINS!

START TO ENJOY THE JOYS OF LIFE AND AVOID THE PAINS OF INVESTING!

More on Premium Service